China’s largest contract research organization WuXi PharmaTech (NYSE: WX) and Hawaii-based TruTag Technologies, the developer of an edible, covert security platform to address the trillion dollar global counterfeit challenge, have successfully completed joint testing of TruTag's on-dose authentication solution.
TruTags offer a unique solution for drug manufacturers, allowing a digital scan of a drug to confirm its authenticity and reveal provenance information such as manufacturing location, dosage, images of packaging, expiration date, supply chain data, and lot or batch number. WuXi and TruTag Technologies announced their alliance in 2014, including an investment by the WuXi Venture Fund in TruTag.
Benefits for drugmakers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze